Oops. Back in June, I sort of, um, laughed off the idea that analysts might look at Pfizer's
The latest entrant is Britain's GlaxoSmithKline
Why the deal? Vaccines, my friends, vaccines. Glaxo wants to expand its vaccine business, and ID Biomedical has some appealing technology and infrastructure that should lead to future returns. And this deal is mostly about the future -- ID Biomedical's Fluviral vaccine is still awaiting FDA approval (albeit on the fast track) and likely won't be available until the '06 flu season. What's more, the Canadian biotech is in the midst of a manufacturing expansion that will allow the company to produce about 75 million flu doses in 2007.
Beyond Fluviral, the company has many other irons in the fire, including vaccines for streptococcal, meningococcal, and pneumococcal infections, as well as for potentially weaponized diseases like plague and anthrax. Longer term, the company also has pre-clinical efforts aimed at vaccines for allergies and asthma, as well as therapies for infections and Alzheimer's.
Certainly, it's not as though Glaxo is completely deficient in the vaccine game. The company received approval for its Fluarix vaccine at the end of August. But this sort of deal will augment its present technology and perhaps make it a more formidable player amongst the likes of Chiron
Unlike a lot of biotech deals where the philosophy is "pay now and hope to get paid back later," ID Biomedical should produce real returns fairly promptly. It's unrealistic to expect that all of the biotech's clinical programs will bear fruit, but it does look like Glaxo has secured a solid asset in the vaccine industry.
For more healthful takes:
- Will Flu Vaccine Catch Cold?
- Novartis Keeps Gorging
- Sanofi-Aventis: A Mix of News
- Farewell, Sweet Vicuron
To see how our technique for finding undervalued stocks or to see the bargains we find, sign up for a free one-month trial to Motley Fool Inside Value. You'll be able to read every newsletter from the past year, including Philip's original Omnicare recommendation. (Pfizer is also an Inside Value recommendation.) Plus, September's newsletter re-examines every pick from the last year and highlights our top recommendations for new money now. Clickhereto join thousands of subscribers beating the market using the techniques master investors have used for decades.